12:00 AM
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

VX-509: Phase IIb start

This month, Vertex will begin a 6-month, international Phase IIb trial to evaluate once and twice-daily VX-509 plus...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >